A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with <sup>18</sup> F-DCFPyL in Prostate Cancer Patients (OSPREY)
-
- Kenneth J. Pienta
- The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland
-
- Michael A. Gorin
- The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland
-
- Steven P. Rowe
- The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
-
- Peter R. Carroll
- University of California San Francisco, San Francisco, California
-
- Frédéric Pouliot
- CHU de Quebec and Laval University, Quebec City, Quebec
-
- Stephan Probst
- Jewish General Hospital, Montreal, Quebec
-
- Lawrence Saperstein
- Yale School of Medicine, New Haven, Connecticut
-
- Mark A. Preston
- Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts
-
- Ajjai S. Alva
- University of Michigan, Ann Arbor, Michigan
-
- Akash Patnaik
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois
-
- Jeremy C. Durack
- Memorial Sloan Kettering Cancer Center, New York, New York
-
- Nancy Stambler
- Progenics Pharmaceuticals, Inc., New York, New York
-
- Tess Lin
- Progenics Pharmaceuticals, Inc., New York, New York
-
- Jessica Jensen
- Progenics Pharmaceuticals, Inc., New York, New York
-
- Vivien Wong
- Progenics Pharmaceuticals, Inc., New York, New York
-
- Barry A. Siegel
- Mallinckrodt Institute of Radiology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri
-
- Michael J. Morris
- Memorial Sloan Kettering Cancer Center, New York, New York
収録刊行物
-
- Journal of Urology
-
Journal of Urology 206 (1), 52-61, 2021-07
Ovid Technologies (Wolters Kluwer Health)
